A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1097-1104

  Hampel Jr , Frank ^a   Gillen, Michael ^b   Rohatagi, Shashank S ^b   Lim, Janet ^b   Georges, George ^b  

^a Central Texas Health Research   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EBASTINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; BACKACHE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EPISTAXIS; FEMALE; FOOD DRUG INTERACTION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PHARYNGITIS; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SINUSITIS; SOMNOLENCE; STATISTICAL ANALYSIS; STEADY STATE; STRUCTURE ACTIVITY RELATION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; BUTYROPHENONES; CHILD; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036786418     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382696     Document Type: Article

References (17)

1. Jones NS, Carney AS, Davis A: The prevalence of allergic rhinosinusitis: a review. J Laryngol Otol 1998;112:1019-1030.
2. Lund VJ: Seasonal allergic rhinitis: a review of current therapy. Allergy 1996;51(suppl. 28):5-7.
3. Pedinoff AJ: Approaches to the treatment of seasonal allergic rhinitis. South Med J 1996;89:1130-1139.
4. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C: A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-27.
5. Scadding GK: Clinical assessment of antihistamines in rhinitis. Clin Exp Allergy 1999;29(suppl. 3):77-81.
6. Meltzer EO: Pharmacological treatment options for allergic rhinitis and asthma. Clin Exp Allergy 1998;28(suppl. 2):27-36.
7. Wiseman LR, Faulds D: Ebastine: a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs 1996;51:260-277.
8. Ratner PH, Lim JC, Georges GC: Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol 2000;105(6, Pt. 1): 1101-1107.
9. Vincent J, Liminana R, Meredith PA, Reid JL: The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 1988;26:497-502.
10. Sjöqvist F, Borgå O, Dahl M-L, Orme ML'E: Fundamentals of clinical pharmacology, in: Speight TM, Holford NHG (eds.), Drug Treatment. 4th ed. Auckland, New Zealand: Adis International, 1997;1-73.
11. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
12. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA: Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-776.
13. Slater JW, Zechnich AD, Haxby DG: Second-generation antihistamines: a comparative review. Drugs 1999;57:31-47.
14. Hismanal monograph, in: Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co., 2001.
15. Claritin monograph, in: Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co., 2001.
16. Haria M, Fitton A, Peters DH: Loratadine: a reappraisal of its pharmacological properties, and therapeutic use in allergic disorders. Drugs 1994;48:617-637.
17. Stoltz M, Arumugham T, Lippert C, Yu D, Bhargava V, Eller M, et al: Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 1997;18:645-648.